Open access · CC-BY
via OpenAlex
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Ryan W. Dellinger, Santiago Roel Santos, Mark Morris, Malkanthi Evans, Dan Alminana, Leonard Guarente, Eric Marcotulli
npj Aging and Mechanisms of Disease · 2017 · ▲ 184 citations
Abstract
Abstract NRPT is a combination of nicotinamide riboside (NR), a nicotinamide adenine dinucleotide (NAD +) precursor vitamin found in milk, and pterostilbene (PT), a polyphenol found in blueberries. Here, we report this first-in-humans clinical trial designed to assess the safety and efficacy of a repeat dose of NRPT (commercially known as Basis). NRPT was evaluated in a randomized, double-blind, and placebo-controlled study in a population of 120 healthy adults between the ages of 60 and 80 years. The study consisted of three treatment arms: placebo, recommended dose of NRPT (NRPT 1X), and double dose of NRPT (NRPT 2X). All subjects took their blinded supplement daily for eight weeks. Analysis of NAD + in whole blood demonstrated that NRPT significantly increases the concentration of NAD + in a dose-dependent manner. NAD + levels increased by approximately 40% in the NRPT 1X group and approximately 90% in the NRPT 2X group after 4 weeks as compared to placebo and baseline. Furthermore, this significant increase in NAD + levels was sustained throughout the entire 8-week trial. NAD + levels did not increase for the placebo group during the trial. No serious adverse events were reported in this study. This study shows that a repeat dose of NRPT is a safe and effective way to increase NAD + levels sustainably.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41514-017-0016-9
- Canonical
- link ↗
- Fetched
- 2026-06-16 MST
Cite this
APA
Dellinger, R.W., Santos, S.R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. <em>npj Aging and Mechanisms of Disease</em>. https://doi.org/10.1038/s41514-017-0016-9
Vancouver
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease. 2017. doi:10.1038/s41514-017-0016-9.
BibTeX
@article{ryan2017Repeat,
title = {Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study},
author = {Ryan W. Dellinger and Santiago Roel Santos and Mark Morris and Malkanthi Evans and Dan Alminana and Leonard Guarente and Eric Marcotulli},
journal = {npj Aging and Mechanisms of Disease},
year = {2017},
doi = {10.1038/s41514-017-0016-9},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
BMC Nephrology 2020
Open access · CC-BY
Nicotinamide riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Nature Communications 2023
Open access · CC-BY
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
Scientific Reports 2019
Open access · CC-BY
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
GeroScience 2022
Open access · CC-BY
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Revision Skincare 2019
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of an Anti-Aging Serum in the Treatment of Facial Lines
Scientific Reports 2023
Open access · CC-BY